Risk of a decline in orders for testing products following COVID-19’s reclassification to Class 5
First written in FY2023-Q2. 3 of 7 entries say "Materialised", first in FY2023-Q3. Latest entry: FY2025-H1.
ImageONE moved to the "Worse" side of this theme in 2023, 1 year after the typical company in this theme (2022).
The whole theme swung hardest in 2022: 5 of 7 companies on the "Worse" side.
0 other companies' latest entry also says "Worsened".
- FY2025-H1WorsenedAnnual report
「In the Medical Supplies segment, as COVID-19 symptoms continued to ease, demand for antigen test kits declined from the previous fiscal year, resulting in sales and profit substantially below the same period of the previous year.」
Demand for infectious-disease-related products has continued to contract following the Class 5 reclassification, with the decline in demand for antigen test kits reflected in business performance. - FY2024WorsenedAnnual report
「Meanwhile, as COVID-19 improves and infection-control measures are relaxed, order-taking activities for existing products such as antigen test kits and PCR detection reagents are expected to contract further.」
Demand and orders for testing-related products have continued to decline following the Class 5 reclassification and are expected to contract further. - FY2024-Q2WorsenedAnnual report
「As COVID-19 symptoms continued to ease and infection-control measures were relaxed, demand for antigen test kits, PCR detection reagents and other products declined, and order activity for antigen test kits and other products contracted.」
The decline in orders for testing products following the Class 5 reclassification has continued, with contracting demand reflected in significant year-on-year declines in revenue and profit. - FY2024-Q1MaterialisedAnnual report
「Meanwhile, because COVID-19 was reclassified under the Infectious Diseases Control Act in May 2023 to Class 5, the same category as seasonal influenza, demand for antigen test kits, PCR detection reagents and other products has continued to contract. As a result, both revenue and profit fell significantly below the same period of the previous year.」
The risk of declining orders for testing products following the Class 5 reclassification has continued to materialize as contracting demand for antigen test kits, PCR detection reagents and other products, along with lower revenue and profit. - FY2023MaterialisedAnnual report
「Meanwhile, because COVID-19 was reclassified under the Infectious Diseases Control Act from May to Class 5, the same category as seasonal influenza, order-taking activities for antigen test kits and other products have been trending downward.」
The risk of declining orders for testing products following the Class 5 reclassification has materialized as shrinking full-year demand for antigen test kits, PCR detection reagents and other products. - FY2023-Q3MaterialisedAnnual report
「Because COVID-19 was reclassified under the Infectious Diseases Control Act from May to Class 5, the same category as seasonal influenza, order-taking activities for antigen test kits and other products have been trending downward.」
The risk of declining orders for testing products following the Class 5 reclassification identified in the previous quarter has materialized as an actual downward trend in order-taking activities for antigen test kits and other products. - FY2023-Q2First statedAnnual report
「In April 2023, the government decided to lower the classification of COVID-19 under the Infectious Diseases Control Act to Class 5, the same category as seasonal influenza, effective 8 May 2023. As a result, concern has arisen over the impact on future order-taking activities for antigen test kits and other products.」
Following the reclassification of COVID-19 as a Class 5 disease, the company explicitly identified the potential impact on future order-taking activities for antigen test kits and other products as a new risk.